Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
Arthritis & Rheumatism2009Vol. 60(4), pp. 976–986
Citations Over TimeTop 1% of 2009 papers
Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Gerald G. Krueger, Dafna D. Gladman, Juan J. Gómez‐Reino, Kim Papp, Julie Zrubek, S. Mudivarthy, M. Mack, Sudha Visvanathan, Anna Beutler
Abstract
Treatment with golimumab at doses of 50 mg and 100 mg significantly improved active PsA and associated skin and nail psoriasis through week 24.
Related Papers
- → Treatment of Psoriatic Arthritis with Tumor Necrosis Factor Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)(2012)51 cited
- → Economic impact of biologic utilization patterns in patients with psoriatic arthritis(2017)16 cited
- → Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany(2017)14 cited
- → The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use(2015)12 cited
- → AB1367 Persistency with subcutaneous anti-TNF therapy for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients(2012)